Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
JERSEY, Channel Islands, Nov. 15, 2016 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chairman and Chief Executive Officer, Paul Cowan, will present at the Jefferies 2016 London Healthcare Conference in London, UK on Thursday, November 17 at 4.00 p.m. GMT (11.00 a.m. Eastern Time).
A live audio webcast of the presentation will be available online from the investor relations page of the Company’s corporate website at www.quotientbd.com. A webcast replay will be archived on the website for approximately 45 days.
About Quotient Limited
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQTM technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The company’s operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.
Contact: Paul Cowan, Chairman & Chief Executive Officer – [email protected]; 215-497-7006
